Innoviva, Inc. cotiza a 20.74 USD y tiene una capitalización bursátil de $1.5B. En los últimos 12 meses ha facturado $440M con un margen de flujo de caja libre del 47.6%. Cotiza a 7.9 veces su flujo de caja libre (P/FCF) y a un PER de 4.2. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining …
| Métrica | INVA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 74.8% | 57.0% | +17.8% |
| Operating Margin | 39.8% | -38.6% | +78.4% |
| Net Margin | 65.9% | -33.6% | +99.5% |
| FCF Margin | 47.6% | -13.9% | +61.5% |
| ROE | 23.1% | -40.4% | +63.5% |
| ROA | 16.6% | -32.0% | +48.6% |
| Current Ratio | 14.64 | 2.84 | +11.80 |
| Debt / Equity | 0.22 | 0.28 | -0.06 |